TNFSF10 and neoplasm: MSCs-FL-TRAIL showed superiority over MSCs-sTRAIL in terms of inducing anti-tumor effects in lung cancer lines, malignant pleural mesothelioma lines, colon cancer lines, renal cancer lines, oral squamous cell carcinoma line, and breast adenocarcinoma line (in vitro)